A HemOncToday article outlines results for a thyroid cancer clinical trial led by Matthew Taylor, M.D. “It’s exciting to see that this is such a relevant molecular target, and that it can be targeted with a highly selective specific drug that doesn’t cause as many off-target side effects as the other drugs in the market,” says Taylor.
OHSU in the news
An article that reviews the safest infant travel equipment - such as strollers, car seats and cribs – includes insight from Ben Hoffman, M.D.: “The car safety seat is going to do a much better job of protecting a kid in the event of turbulence than just a lap belt alone.”
OHSU hosts its first-ever conference to provide information and resources regarding integrative medicine options like massage, acupuncture, and more for patients going through cancer treatment. Susan Hedlund, M.S.W., says: “We don't want people to just survive. We want people to thrive. And the integrative medicine adds to that possibility”
Blueprint Medicines presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO
New data from the NAVIGATOR trial, led by Michael Heinrich, M.D., demonstrate clinical activity and favorable tolerability in patients with a rare form of stomach cancer.
Tony Rianprakaisang, M.D., discusses a 2018 patient case study wherein a child experienced negative health impacts following the utilization of CBD oil that included the synthetic cannabinoid AB-FUBINACA.
An opinion article written by Jason Campbell M.D., explores the importance of mentorship, inclusion and mindfulness in helping African-American children succeed.
The Portland Business Journal quotes Mark Slifka, Ph.D., and Nancy Haigwood, Ph.D., regarding the work of OHSU spinout company Najit Technologies Inc., in developing vaccines targeting mosquito-borne illnesses common to the developing world.
In a KATU-TV story exploring the use of CBD to treat opioid use disorder, Devan Kansagara, M.D., says: “There’s been a ton of interest in CBD and in cannabis in general. I think the research needs to catch up in the public’s interest in it.”
OHSU Doernbecher utilizes the Locus Health digital platform to improve follow-up care for cardiology and NICU patients.
Low response rate for checkpoint inhibitors underscores ‘unrealistic expectations’ about their effectiveness
A multi-year, cross-sectional analysis study led by Alyson Haslam, Ph.D., and Vinay Prasad, M.D., M.P.H., suggests that, despite an increase in FDA approval for immune checkpoint inhibitor drugs for patients with cancer, an estimated fewer than 13% of patients with cancer respond to the treatment.
- Latest Stories